A total of 91 patients received TL-118 or TL-112/TL-111 (which are former formulations of TL-118 containing the same active components but differ in excipients) as summarized in Table  below.

Title

Study ID/

Status

Design

Enrolled

Subjects

(N)

Treatment

Formulation

 (N)

Treatment

Duration

(weeks)

Hamsa-1 metastatic CRPC

TLH-202

Closing

Open-label single arm Assessment of product efficacy, safety and tolerability

49

TL-112 - 31

TL-118 - 18

Range: 1-70

Mean: 13

Median: 8

Hamsa-1 Solid Tumors

4237/2006

Completed

Open-label single arm Assessment of product safety and preliminary efficacy

31

TL-111/

TL-112

Range: 2-151

Mean: 21

Median: 12

Hamsa-1 Glioblastoma

07-208

Completed

Open-label single arm Assessment of product safety and preliminary efficacy

11

TL-112

Range: 1-13

Mean: 6.8

Median: 4

Built by Badboy.co.il

© copyright 2015 Tiltan Pharma